<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011516</url>
  </required_header>
  <id_info>
    <org_study_id>818755</org_study_id>
    <secondary_id>CURE CANN</secondary_id>
    <nct_id>NCT02011516</nct_id>
  </id_info>
  <brief_title>Baclofen Effects on Marijuana Dependence</brief_title>
  <official_title>A Randomized Placebo-controlled Study of Baclofen on Brain and Behavioral Outcomes in Marijuana Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pennsylvania Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies show that certain reminders of drug use such as the sight of someone using marijuana,
      pictures of blunts, particular moments throughout the day, prompt marijuana users to smoke
      marijuana. We are measuring the brain and behavioral responses of marijuana dependent
      individuals to these reminders (cues) We will examine brain responses during cue exposure and
      determine whether these responses are associated with treatment outcome.

      We are testing the hypothesis that the medication baclofen reduces brain responses during
      marijuana cue exposure and/or craving in marijuana dependent individuals. Baclofen is
      FDA-approved for other uses, but not for the treatment of marijuana dependence. Functional
      magnetic resonance imaging (fMRI) will be used to measure the brain's response to marijuana
      cues. fMRI is a painless technique that takes special pictures of the brain (or other parts
      of your body). It does not involve radiation or injections.

      Eligible participants will have a 50% chance of receiving placebo (sugar pill) and a 50%
      chance of receiving baclofen. Neither the participant nor study personnel will know whether
      participants are receiving baclofen or placebo. Participants will also receive twice weekly
      psychosocial treatment with a certified clinician. Twelve weeks of treatment will be followed
      by a 12 week follow up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine Drug Screen</measure>
    <time_frame>study weeks 1-12</time_frame>
    <description>Change from positive to negative over the 12 weeks of a medication regimen</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Marijuana Dependence</condition>
  <arm_group>
    <arm_group_label>Sugar pill, psychosocial intervention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>twice weekly appointments with a certified clinician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baclofen, psychosocial intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg. q.i.d. twice weekly appointments with a certified clinician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <arm_group_label>Baclofen, psychosocial intervention</arm_group_label>
    <other_name>Kemstro</other_name>
    <other_name>Lioresal</other_name>
    <other_name>Liofen</other_name>
    <other_name>Gablofen</other_name>
    <other_name>Beklo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychosocial</intervention_name>
    <arm_group_label>Sugar pill, psychosocial intervention</arm_group_label>
    <arm_group_label>Baclofen, psychosocial intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sugar pill, psychosocial intervention</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physically healthy, as determined by a comprehensive physical examination and approval
             of the study physician, and mentally stable, as determined by a psychological
             evaluation by a licensed clinician, males or females who meet Diagnostic and
             Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for marijuana dependence,
             ages 18-60.

          -  Must be able to read. [Subjects are required to be able to read because there are
             several self-administered measures that they must read, understand and provide written
             answers.]

          -  Females must be non-pregnant, non-lactating and either be of non-childbearing
             potential (i.e. sterilized via hysterectomy or bilateral tubal ligation or at least 1
             year post-menopausal) or of child bearing potential but practicing a medically
             acceptable method of birth control. Examples of medically acceptable methods for this
             protocol include barrier (diaphragm or condom) with spermicide, an intrauterine device
             (IUD), the Nuvaring, oral contraceptives, levonorgestrel implant, hormonal injection
             or complete abstinence.

          -  Intelligence quotient of â‰¥ 80.

          -  Provide voluntary informed consent.

        Exclusion Criteria:

          -  Participation in a clinical trial and receipt of investigational drug(s) during the
             previous 60 days.

          -  Presence of magnetically active irremovable prosthetics, plates, pins, permanent
             retainer, bullets, etc. (unless a radiologist confirms that it's presence is
             unproblematic). An x-ray may be obtained to determine eligibility given the
             possibility of a foreign body.

          -  Current use of non-removable medicated or nicotine skin patches.

          -  Current or prior gambling problems (assessed by subject's self-report).

          -  Current treatment for marijuana dependence.

          -  Any other current drug dependence diagnoses (except nicotine dependence).

          -  Any other psychiatric diagnoses. Current diagnosis/recent history (within past 6
             months) of Major Depressive Disorder (MDD).

          -  History of head trauma or injury causing loss of consciousness, lasting more than
             three (3) minutes or associated with skull fracture or inter-cranial bleeding or
             abnormal Magnetic Resonance Imaging (MRI).

          -  Claustrophobia or other medical condition preventing subject from lying in the MRI for
             approximately one (1) hour.

          -  Clinically significant cardiovascular, hematologic, hepatic (liver), renal (kidney),
             neurological, or endocrinological abnormalities, bloodwork, and/or electrocardiogram
             (EKG).

          -  Uncontrolled diabetes or uncontrolled hypertension.

          -  History of psychosis, seizures, or organic brain syndrome.

          -  Vision problems that cannot be corrected with glasses.

          -  Weight exceeding 300 pounds [Imaging data acquisition is impaired with high weight
             individuals].

          -  History of stroke.

        Case-by-Case:

          -  Human immunodeficiency virus (HIV) positive on medication for symptoms. This will be
             determined on an individual basis by results from the physical examination and final
             approval by our study physician; all results from the physical within normal range for
             study inclusion.

          -  Use of medications or natural herbs that cause sedation or affect the brain systems
             that are being studied. Medication use will be evaluated by our study physician on a
             case-by-case basis. For example, if the subject takes Benadryl but can safely refrain
             from use 24 hours prior to scanning sessions, they will not be excluded.

          -  Significant history of past alcohol or substance abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa R Franklin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Center for Studies of Addiction</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://franklinbrainimaging.com</url>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <results_first_submitted>November 23, 2016</results_first_submitted>
  <results_first_submitted_qc>June 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Teresa Franklin</investigator_full_name>
    <investigator_title>Research Assistant Professor of Neuroscience in Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Marijuana</keyword>
  <keyword>Addiction</keyword>
  <keyword>fMRI</keyword>
  <keyword>Baclofen</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Timeframe: 12/2013-10/2014
Potential subjects were recruited via word of mouth, flyers, craigslist and targeted Facebook ads
47 potential subjects were enrolled (consented), 41 were screened, 22 passed screening, 21 baseline scan, 16 randomized, 13 treatment scan, 8 post-tx scan, 10 completed.</recruitment_details>
      <pre_assignment_details>All enrolled participants, those that consented to study procedures, participated in a screening process that consisted of a physical and psychological evaluation. Those participants that did not meet our specific inclusion criteria, and/or those that met our exclusion criteria, were not assigned to groups. These individuals were given referrals.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill, Psychosocial Intervention</title>
          <description>twice weekly appointments with a certified clinician
Psychosocial
Placebo</description>
        </group>
        <group group_id="P2">
          <title>Baclofen, Psychosocial Intervention</title>
          <description>20 mg. q.i.d. twice weekly appointments with a certified clinician
Baclofen
Psychosocial</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill, Psychosocial Intervention</title>
          <description>twice weekly appointments with a certified clinician
Psychosocial
Placebo</description>
        </group>
        <group group_id="B2">
          <title>Baclofen, Psychosocial Intervention</title>
          <description>20 mg. q.i.d. twice weekly appointments with a certified clinician
Baclofen
Psychosocial</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urine Drug Screen</title>
        <description>Change from positive to negative over the 12 weeks of a medication regimen</description>
        <time_frame>study weeks 1-12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill, Psychosocial Intervention</title>
            <description>twice weekly appointments with a certified clinician
Psychosocial
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Baclofen, Psychosocial Intervention</title>
            <description>20 mg. q.i.d. twice weekly appointments with a certified clinician
Baclofen
Psychosocial</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Drug Screen</title>
          <description>Change from positive to negative over the 12 weeks of a medication regimen</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>study weeks 1-12</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill, Psychosocial Intervention</title>
          <description>twice weekly appointments with a certified clinician
Psychosocial
Placebo</description>
        </group>
        <group group_id="E2">
          <title>Baclofen, Psychosocial Intervention</title>
          <description>20 mg. q.i.d. twice weekly appointments with a certified clinician
Baclofen
Psychosocial</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Metallic Taste</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal Cramping</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increase in Bowel Movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Unintended Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsy/Sluggish</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Slowed Cognition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>&quot;High&quot; Feeling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size too sample to draw conclusions. No subject was able to provide a negative cannabis urine throughout treatment. A caveat is that cannabis stays in the urine for 6 weeks after final use.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Teresa R. Franklin, Ph.D., Research Associate Professor of Neuroscience in Psychiatry</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-222-3200 ext 119</phone>
      <email>teresafr@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

